You are using an older version of Internet Explorer that is not supported on this site. Please upgrade for the best experience.

David Gang, MD elected President of the Massachusetts Society of Pathologists (MSP)

July 01, 2019
InContentGang250x2502

Dr. David Gang, Professor of Pathology, was elected President of the Massachusetts Society of Pathologists (MSP) in May 2019. He has been a member of the MSP since 1990 and previously served as an At-Large member of the Executive Committee. As President of the MSP, Dr. Gang will organize and run the biannual educational meetings and work with the Executive Committee in supporting political action. He will also work with other Massachusetts physician organizations, the Massachusetts Medical Society, and the legislature on patient-related matters.

In addition to his role as President of MSP, Dr. Gang is the new Chair of the Federal and State Affairs Committee of the College of American Pathologists (CAP). CAP is the world’s largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs. Dr. Gang oversees advocacy on the state, federal, and grassroots level for the College on behalf of patients and fellow pathologists.

This past April, Dr. Gang moderated a full day session at CAP’s yearly Policy meeting in Washington D.C., sharing best practices for effective communication with congressional staff. On the final day of the meeting, Dr. Gang led over 80 pathologists to the Hill where they advocated for legislation to protect patients from surprise medical bills and stressed the importance of the Protecting Access to Medicare Act (PAMA) reform, which is needed to prevent significant reductions in Medicare reimbursement for clinical laboratory tests. The Massachusetts contingent spoke with legislative staff from the offices of Richard Neal, Jim McGovern, Ayanna Pressley, Ed Markey, and Elizabeth Warren, plus with Joe Kennedy directly. Through these meetings, the group emphasized that any federal legislation on surprise billing should include the following goals: set network adequacy standards for hospital-based physicians, provide fair reimbursement for care, and establish an arbitration process to take patients out of the middle.

The PAMA reform would have a direct impact on Baystate Health and Baystate Reference Laboratories in particular, and the work by Dr. Gang and his colleagues to protect patients on federally regulated health plans from the threat of “surprise bills” has a nationwide impact.